Hemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc.

COAG
Last price US$44.84
Market cap US$2.1b
12M price change N/A
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

Hemab Therapeutics Holdings, Inc. Overview

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Sector: Health Care

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patie

Newly listed company coverage

Verified company profile, price history, and SEC registration source are available.

10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.

Review the SEC registration filing

Research snapshot

This Mavefund research page organizes verified information for Hemab Therapeutics Holdings, Inc. (COAG), including the company profile, price history, source-linked filings, available financial statements, research signals, and risks to review.

Listing
COAG · Nasdaq · MIC XNAS
Country
United States
Trading currency
USD
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Coverage is refreshed automatically and published only after data-integrity validation. Research support only; not personalized financial advice.

Reported Results

No latest earnings report cached yet

The latest source-linked annual or interim company filing has not been cached for this ticker yet.

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

No qualified company news in the last 14 days

No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

Financial Statements

Company-reported filing facts, organized and linked to the original source.

Reported currency
Annual 10-K, 20-F, or ESEF financial statement data is not available yet.

Source details load with the filing data. Values are standardized company disclosures for research support, not personalized financial advice.

Hemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc.

US$44.84

US$2.1b

-8.79%

N/A